Preliminary evaluation of Jusvinza as an immunomodulatory therapy in Guillain Barré syndrome
Keywords:
Guillain-Barré syndrome, inflammation, Jusvinza, patientsAbstract
Introduction: Guillain-Barré Syndrome (GBS) is an acute inflammatory polyneuropathy characterized by immune-mediated damage to the peripheral nervous system. Jusvinza is an immunomodulatory drug previously administered to patients with rheumatoid arthritis and COVID-19. Its anti-inflammatory properties support its potential therapeutic application in conditions such as GBS.
Objectives: To evaluate the therapeutic effect and safety of Jusvinza in the treatment of GBS.
Methods: Thirteen patients diagnosed with GBS, primarily associated with respiratory infections, were enrolled following informed consent. Eleven patients received intravenous Jusvinza at a dosage of 1 mg every 8 hours, while the remaining two were treated with standard therapy. Clinical progression, recovery time, duration of stay in the intensive care unit (ICU), adverse events, and discharge status were documented in medical records. These data were subsequently organized and analyzed using comparative tables.
Results: Jusvinza reduced the average recovery time and ICU stay by 18 and 27 days, respectively, compared to standard immunotherapies. No respiratory complications or other adverse events were reported, and no serious side effects were associated with the treatment. All patients showed favorable clinical outcomes and were discharged.
Conclusions: Jusvinza promote rapid clinical improvement in patients with GBS and demonstrated a favorable safety profile, representing a promising starting point for future research.
Downloads
References
1. Hughes RA, Cornblath DR. Guillain-Barré syndrome [Internet]. The Lancet. 2005; 366(9497): 1653-66. DOI: 10.1016/S0140-6736(05)67665-9
2. Shoenfeld Y, George J, Peter JB. Guillain-Barre as Autoimmune disease [Internet]. International Archives of Alergy and Immunology. 1996; 109: 318-326. DOI: 10.1159/000237258
3. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 Antibodies Cause Complement-Mediated Disruption of Sodium Channel Clusters in Peripheral Motor Nerve Fibers [Internet]. J Neurosci. 2007; 27(15): 3956 –67. DOI: 10.1523/JNEUROSCI.4401-06.2007
4. Nguyen TP, Taylor RS. Guillain-Barre Syndrome [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. [acceso: 23/03/2025]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK532254
5. Hartung HP, Toyka KV. T-cell and Macrophage Activation in Experimental Autoimmune Neuritis and Guillain-Barre Syndrome [Internet]. Annals of Neurology.1990; 27: S57-S63. DOI: 10.1002/ana.410270716
6. Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, et al .Ultrastructural mechanisms of macrophage-induced demyelination in CIDP [Internet]. Neurology. 2018; 91: 1-10. DOI: 10.1212/WNL.0000000000006625
7. World Health Organization. Assessment and management of Guillain-Barré syndrome in the context of Zika virus infection [Internet]. WHO, Interim guidance update. 2016 [acceso: 10/03/2025]; 1(16.4): [aprox. 10 pant.]. Disponible en: https://www.who.int/publications/i/item/WHO-ZIKV-MOC-16.4-Rev.1
8. Dominguez MC, Lorenzo N, Barbera A, Darrasse-Jeze G, Hernández MV, Torres A, et al. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis [Internet]. Autoimmunity. 2011; 44(6): 471-82. DOI: 10.3109/08916934.2010.550590
9. Venegas-Rodriguez R, Santana-Sanchez R,Peña-Ruiz R, Bequet-Romero M, Hernandez-Cedeño M, Santiesteban-Licea E, et al. CIGB-258 Immunomodulatory Peptide: Compassionate Use for Critical and Severe COVID-19 Patients [Internet]. Austin J Pharmacol Ther. 2020 [acceso: 22/03/2025]; 8(1):1119. Disponible en: https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v8-id1119.php
10. Baldomero JE, Del Río Martín A, Cruz LR,Venegas R, Hernández M, Serrano A,Peña R, et al. Early Treatment with a Peptide Derived from the Human Heat-Shock 60 Protein Avoids Progression to Severe Stages of COVID-19 [Internet]. J Biotechnol Biomed. 2021; 4(4): 196-210. DOI: 10.26502/jbb.2642-91280045
11. Venegas-Rodríguez R,Serrano-Díaz A, Peña-Ruiz R, Santana R, Hernández-Cedeño M, Rittoles Navarro A, et al. Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study[Internet]. PLoSONE. 2022;18 (2): e0281111. DOI: 10.1371/journal.pone.0281111
12. WMA. World Medical Association Declaration of HelsinkiEthical Principles for Medical Research Involving Human Participants. JAMA; 2025;333;(1):71-74. DOI: 10.1001/jama.2024.21972
13. Ministerio de Salud Pública. Regulación No. 45-2007: Requerimientos para la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos [Internet]. La Habana: CECMED; 2007. [acceso: 22/03/2025]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/reg_4507_requerimientos_para_la_notificacion_y_el_reporte_de-_eventos_adversos_graves_e_inesperados_en_los_ensayos_clinicos.pdf
14. Quan S, Sheng JR,Abraham PM. Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy [Internet]. Clin Exp Immunol. 2016; 184:50-61. DOI: 10.1111/cei.12756
15. Domínguez MC, Lorenzo N, Barberá A, Padrón G, Torres AM ,Hernández MV, et al. Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis [Internet]. Biotecnología Aplicada. 2013 [acceso: 23/03/2025]; 30(2):153-6. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=48194
16. Lorenzo N, Altruda F, Silengo L, Dominguez MC. APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collageninduced arthritis [Internet]. Clin Exp Med. 2017; 17(2):209-16. DOI: 10.1007/s10238-016-0412-7
17. Barberá A, Lorenzo N, Garrido G, Mazola Y, Falcón V, Torres AM, et al . APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients [Internet]. Int Immunopharmacol. 2013; 17(4):1075-83. DOI: 10.1016/j.intimp.2013.10.010
18. Barberá A, Lorenzo N, van Kooten P, van Roon J, de Jager W, Prada D, et al. APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+Tcells from rheumatoid arthritis patients [Internet]. Cell Stress Chaperones. 2016; 21(4):735-44. DOI: 10.1007/s12192-016-0698-0
19. Hernández-Cedeño M, Rodríguez-Ulloa A, Ramos Y, González LJ, Serrano-Díaz A, Zettl K, Wiśniewski JR, et al. Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis Patients [Internet]. Biomedicin. 2024; 29(12):2740. DOI: 10.3390/biomedicines12122740
20. Hernandez-Cedeño M, Venegas-Rodriguez R, Peña-Ruiz R, Bequet-Romero M, Santana-Sanchez R, Penton-Arias E, et al. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients [Internet]. Cell Stress Chaperones. 2021; 26(3):515-25. DOI: 10.1007/s12192-021-01197-2
21. Venegas R, Serrano A, Peña R, Santana R, Rittoles A, Grecesqui I et al. El tratamiento con Jusvinza disminuye la hiperinflamación y la hipercoagulación en pacientes críticos con la COVID-19 [Internet]. Rev Cub Med Mil. 2021 [acceso: 22/03/2025]; 50(4): e02101675. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572021000400018&lng=es
22. Ackermann G, Paw B. Zebrafish: a genetic model for vertebrate organogenesis and human disorders [Internet]. Front Biosci. 2003; 8: d1227-53. DOI: 10.2741/1092
23. Cho KH, Nam HS, Kim JE, Na HJ, Dominguez-Horta MC, Martinez-Donato G. CIGB-258 Exerts Potent AntiInflammatory Activity against CarboxymethyllysineInduced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I [Internet]. Int J Mol Sci. 2023; 24:7044. DOI: 10.3390/ijms24087044
24. Cho KH, Bahuguna A, Lee Y, Lee SH, Dominguez-Horta MC, Martinez-Donato G. Synergistic Anti Inflammatory Activity of Lipid-Free Apolipoprotein (apo) A-I and CIGB-258 in Acute-Phase Zebrafish via Stabilization of the apoA-I Structure to Enhance Anti-Glycation and Antioxidant Activities [Internet]. Int J Mol Sci. 2024; 25(10): 5560. DOI: 10.3390/ijms25105560
25. Cho KH, Kim JE, Kang DJ, Dominguez-Horta MC, Martinez-Donato G. Synergistic Anti-Inflammatory Activity of Apolipoprotein A-I and CIGB-258 in Reconstituted High-Density Lipoproteins (rHDL) against Acute Toxicity of Carboxymethyllysine in Zebrafish and Its Embryo [Internet]. Pharmaceuticals. 2024; 17(2):165. DOI: 10.3390/ph17020165
26. IWMF: International Waldenstrom´s Macroglobulinemia Foundation. Ficha técnica de la Plasmaféresis [Internet]. IWMF; 2015. [acceso: 10/03/2025]. Disponible en: https://iwmf.com/wp-content/uploads/2020/10/Plasmapheresis-Fact-Sheet-Spanish.pdf
27. Centro para el Control Estatal de Medicamentos Equipos y Dispositivos Médicos. Resumen de las características del producto Intacglobin [Internet]. Cuba, La Habana: CECMED; 2013. [acceso: 20/03/2025]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_intacglobin_5_2013-12-19.pdf
28. Domínguez-Horta MDC, Serrano-Díaz A, Hernández-Cedeño M, Martínez-Donato G, Guillén-Nieto G. A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation [Internet]. Front Immunol. 2023; 28(14):1162739. DOI: 10.3389/fimmu.2023.1162739.89
29. Prada D , Gómez J, Lorenzo N, Corrales O, López A, González E, et al. Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects [Internet]. Journal of Clinical Trials. 2018; 8(1):1000339. DOI: 10.4172/2167-0870.1000339
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Raúl Santana-Sanchez R, Anabel Serrano-Díaz, Rubén Peña-Ruiz, Mabel Hernandez-Cedeñp, Gillian Martinez-Donato , Rafael Venegas-Rodriguez, María del Carmen Domínguez Horta
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
